PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage

This publication has 59 references indexed in Scilit:

• Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus
  Nephrology Dialysis Transplantation, 2009
• Ciglitazone induces apoptosis via activation of p38 MAPK and AIF nuclear translocation mediated by reactive oxygen species and Ca2+ in opossum kidney cells
  Toxicology, 2009
• Cyclooxygenase-2 Mediates Dialysate-Induced Alterations of the Peritoneal Membrane
  Journal of the American Society of Nephrology, 2009
• Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients
  Journal of Clinical Pharmacy and Therapeutics, 2008
• Epithelial-to-mesenchymal transition of peritoneal mesothelial cells is regulated by an ERK/NF-κB/Snail1 pathway
  Disease Models & Mechanisms, 2008
• Diversity in the contribution of interleukin‐10 to T‐cell‐mediated immune regulation
  Immunological Reviews, 2008
• Ciglitazone induces caspase-independent apoptosis via p38-dependent AIF nuclear translocation in renal epithelial cells
  Toxicology, 2008
• Epithelial to Mesenchymal Transition and Peritoneal Membrane Failure in Peritoneal Dialysis Patients
  Journal of the American Society of Nephrology, 2007
• Peroxisome Proliferator-Activated Receptor-γ Agonists Diminish Peritoneal Functional and Morphological Changes Induced by Bioincompatible Peritoneal Dialysis Solution
  Blood Purification, 2006
• Damage to the Peritoneal Membrane by Glucose Degradation Products Is Mediated by the Receptor for Advanced Glycation End-Products
  Journal of the American Society of Nephrology, 2006